CDK1 and breast cancer: In contrast, the potent cyclin dependent kinase inhibitor p21 which binds to and inhibits the activity of cyclin-CDK2, -CDK1, and -CDK4/6 complexes, was dose-dependently upregulated in both breast cancer cell lines and to a lesser extend in MCF-10A (Figure 1).